Today in History for Feb. 17: ...

The split will allow WBD to take advantage of "broader market opportunities" as they arise, CEO David Zaslav told analysts.

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...

Novavax reported a Q4 2024 EPS of -$0.51, surpassing expectations. Revenue for the quarter fell to $88.3 million, missing forecasts and down from $291 million in Q4 2023. The company reduced R&D ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%.

Bullish option flow detected in Novavax (NVAX) with 23,789 calls trading, 3x expected, and implied vol increasing over 8 points to 114.25%. Feb-25 8.5 calls and Mar-25 7.5 puts are the most active ...

Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic. Novavax (NVAX) closed the most recent trading day at $7.92, moving -1.25% from the ...